Germany’s Fresenius has acquired a controlling stake in Indian oncology specialist Dabur Pharma in a deal worth €139m.
The group says its Fresenius Kabi unit is continuing its growth strategy in intravenously administered drugs.
Dabur, based in New Delhi, makes generics and active pharmaceutical ingredients to treat cancer.
It holds several drug registrations in Asia, Europe and the USA and says it is one of the few manufacturers worldwide to hold international registrations “for all steps within the manufacturing process of cytostatic agents”.
Dabur operates two production facilities in India and one in the UK, plus an R&D centre near New Delhi that meets European and US standards.
Dabur is to supply Fresenius Kabi’s compounding centres in Europe, the Asia-Pacific region and Latin America, where patient-specific formulations of IV drugs and parenteral nutrition are prepared for cancer patients.
Dabur founder and director Anand Burman told India’s Economic Times that with more than 20,000 drugmakers in India, the industry had to consolidate.